Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients

• Published in: BMC cancer Vol. 16; no. 1; p. 860
• Main Authors: Monroy-Cisneros, Karina, Esparza-Romero, Julián, Valencia, Mauro E, Guevara-Torres, Alfonso G, Méndez-Estrada, Rosa O, Anduro-Corona, Iván, Astiazarán-García, Humberto
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.11.2016; BioMed Central
• Subjects: Adult; Alfacalcidol; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor; Bone Density; Bone Diseases - etiology; Bone Diseases - pathology; Bone resorption; Breast cancer; Breast Neoplasms - complications; Breast Neoplasms - diagnosis; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Calcifediol; Cancer; Care and treatment; Chemotherapy; Diagnosis; Dosage and administration; Female; Health aspects; Humans; Menopause; Mexico; Middle Aged; Neoplasm Staging; Postmenopausal women; Risk Factors; Vitamin D; Bone resorption; Chemotherapy; Calcium; Menopause; Breast neoplasm
• DOI: 10.1186/s12885-016-2905-x
• ISSN: 1471-2407

Breast cancer is the most deadly malignancy in Mexican women. Although treatment has improved, it may significantly affect bone mineral status in those who receive it. The aim of this study was to assess the impact of cancer treatment on bone mineral density (BMD) and bone mineral content (BMC), in patients with breast cancer and explore the interaction of menopausal status and clinical stage with cancer treatment on such changes. A quasi-experimental design was applied with measurements before and after a chemotherapy treatment in 40 patients with primary diagnosis of invasive breast cancer. BMD and body composition measurements were taken by dual X-ray absorptiometry (DXA) and changes in these variables due to therapy were analyzed using mixed regression for repeated measurements. Significant loss was found in femoral neck and L2-L4 BMD (p < 0.001). Patients diagnosed with osteopenia or osteoporosis received calcium + vitamin D supplementation (600 mg/200 IU day). It showed a protective effect in the decrease of femoral neck BMD and total BMC. BMD loss in both femoral neck and L2-L4 BMD was higher in premenopausal women: 0.023 g/cm in femoral neck and 0.063 g/cm in L2-L4 (p < 0.001), while in postmenopausal women BMD loss was 0.015 g/cm in femoral neck and 0.035 g/cm in L2-L4 (p = 0.021 and p = 0.001 respectively). Change in lumbar spine BMD was prominent in premenopausal women with advanced clinical stage (IIB, IIIA, IIIB): 0.066 g/cm (p = 0.003). The antineoplastic breast cancer treatment with chemotherapy had a negative impact on BMD, in premenopausal women overall, although a differential effect was found according to clinical stage and calcium supplementation status.